Dr Edwin Moses

Chairman

Edwin Moses was Chief Executive Officer of Ablynx NV until its agreed takeover by Sanofi for $4.8 billion in 2018. He was CEO of Ablynx for more than 12 years and built it from a small R&D-focused organisation into a 500-person commercial-ready business. The company developed a broad biologics pipeline including a wholly-owned product for a rare hematologic indication, which was approved for use in Europe in 2018 and the USA in 2019. While at Ablynx, Edwin led its Euronext Brussels listing, multiple successful private and public financings and its US NASDAQ listing in 2017 which raised $230M. He was also responsible for delivering a series of multi-billion-pound collaborations with major pharmaceutical companies.

Edwin has more than 25 years of Board level experience, both as CEO and Chairman, at more than 10 European life science companies. During his career to date, he has raised more than €500M in equity and debt financing. Edwin is currently also Chair of Achilles Therapeutics plc and Avantium NV.